Daiichi Sankyo Europe, Gmbh, A Daiichi Sankyo Company
Clinical trials sponsored by Daiichi Sankyo Europe, Gmbh, A Daiichi Sankyo Company, explained in plain language.
-
Tracking a new hope for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study aims to understand how well a targeted drug called trastuzumab deruxtecan works for people with advanced, hard-to-treat breast cancer that has a specific marker (HER2-low). It will follow over 1,100 patients in Europe who are already receiving this drug or standard che…
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Tracking a promising new drug for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis study aims to see how well the drug trastuzumab deruxtecan (T-DXd) works for adults with advanced HER2-positive stomach or gastroesophageal junction cancer who have already received a prior similar treatment. It will observe about 257 patients in Europe who are already presc…
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Triple-Drug attack on high cholesterol tested in major Real-World study
Disease control Recruiting nowThis study is observing how well a combination of three cholesterol-lowering drugs works for people in everyday medical practice. It will follow 2,000 adults with high cholesterol who are already taking this specific triple therapy to see how much it lowers their 'bad' LDL choles…
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control
Last updated Mar 09, 2026 14:26 UTC